Safety Data Sheet Product Name: Equisolon 33.3 mg/g oral powder Issue Date: 08/2021

Version No: 2021-1



SECTION 1: IDENTIFICATION			
1.1 Product identifier			
Product name	Equisolon 33.3 mg/g oral powder		
Synonyms	Not available		
Proper shipping name	Not available		
Other means of	None		
identification			
1.2 Relevant identified uses of the substances or mixture and uses advised against			
Recommended uses	Alleviation of inflammatory and clinical parameters associated		
	with recurrent airway obstruction in horses, in combination with		
	environmental control		
Uses advised against	Not for human use		
1.3 Details of the supplier of the substance or mixture			
Registered company	Dechra Ltd		
name			
Address	Snaygill Industrial Estate		
	Keighley Road		
	Skipton		
	North YorkshireBD23 2RW		
	UK		
Telephone	+44 (0) 1756 791311		
Fax	+44 (0) 1756 798604		
Email	Not available		
1.4 Emergency telephone numbers			
Dechra (US)	+44 (0) 1756 791311		

SECTION 2: HAZARDS IDENTIFICATION				
2.1 Classification of the substance or mixture				
Classified according to Regulation (EC) No1272/2008	Acute toxicity, Oral (Category 4)			
Classified according to European Directive 67/548/EEC as amended 2.2 Label elements	Harmful: danger of serious damage to health by prolonged exposure through inhalation, in contact with skin and if swallowed.			
Hazard pictogram(s)	<u>(!)</u>			
Signal word	Warning			
2.3 Hazard statement(s)				
H302	Harmful if swallowed.			

Safety Data Sheet Product Name: Equisolon 33.3 mg/g oral powder Issue Date: 08/2021

Version No: 2021-1



2.4 Precautionary statement(s)			
P264	Wash all exposed external body areas thoroughly after		
	handling.		
P270	Do not eat, drink or smoke when using this product.		
P301 + P312	IF SWALLOWED: Call a POISON CENTER or		
	doctor/physician if you feel unwell		
P330	Rinse mouth.		
P501	Dispose of contents/container in accordance with local		
	regulations.		
2.5 Hazard symbol(s)			
Xn	Harmful		
2.6 R-phrase(s)			
R48/20/21/22	Harmful: danger of serious damage to health by prolonged		
	exposure through inhalation, in contact with skin and if		
	swallowed.		
2.7 S-phrase(s)			
S7	Keep container tightly closed.		
S15	Keep away from heat.		
S33	Take precautionary measures against static discharges.		
	Wear suitable protective clothing, gloves and eye/face		
	protection.		
S36/37/39	Wear suitable protective clothing, gloves and eye/face		
	protection.		
S46	If swallowed seek medical advice immediately and show		
	this container or label.		

SECTION 3: INFORMATION ON THE INGREDIENTS						
3.1 Substances						
Name	EC No.	CAS No.	Classification under CLP Regulation	Classification under Directive 67/548/EEC		
Prednisolone	200-021-7	50-24-8	H302	R48/20/21/22		
Synonyms	1-Dehydrocortisol 1-Dehydrohydrocortisone 1,4-Pregnadiene-11β,17∝,21-triol-3,20-dione 11β,17∝,21-Trihydroxy-1,4-pregnadiene-3,20-dione					
Formula	$C_{21}H_{28}O_5$					
Molecular Wei	360.44 g/mc	ol				

Product Name: Equisolon 33.3 mg/g oral powder Issue

Date: 08/2021 Version No: 2021-1



#### **SECTION 4: FIRST AID MEASURES**

### **Description of first aid measures**

#### General advice:

Consult a physician. Show this safety data sheet to the doctor in attendance.

#### Eve contact:

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

#### Skin contact:

Wash off with soap and plenty of water. Consult a physician.

#### Inhalation:

If breathed in, move person into fresh air. If not breathing give artificial respiration Consult a physician.

### Ingestion:

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

#### **SECTION 5: FIRE FIGHTING MEASURES**

#### 5.1 Extinguishing media:

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

# **5.2 Special protective actions for fire-fighters:**

Wear self contained breathing apparatus for fire fighting if necessary.

### **SECTION 6: ACCIDENTAL RELEASE MEASURES**

# 6.1 Personal precautions, protective equipment and emergency procedures:

Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Ensure adequate ventilation.

#### 6.2 Environmental precautions:

Do not let product enter drains.

#### 6.3 Methods and material for containment and cleaning up:

Pick up and arrange disposal without creating dust. Keep in suitable, closed containers for disposal.

### **SECTION 7: HANDLING AND STORAGE**

#### 7.1 Precautions for safe handling:

Avoid formation of dust and aerosols.

Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.

#### 7.2 Conditions for safe storage:

Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

Product Name: Equisolon 33.3 mg/g oral powder Issue

Date: 08/2021 Version No: 2021-1



SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION				
Personal protective equipment				
Respiratory	Where risk assessment shows air-purifying respirators are appropriate			
protection	use a dust mask type N95 (US) or type P1 (EN 143) respirator. Use			
	respirators and components tested and approved under appropriate			
	government standards such as NIOSH (US) or CEN (EU).			
Hands	The selected protective gloves have to satisfy the specifications of EU			
protection	Directive 89/686/EEC and the standard EN 374 derived from it.			
	Handle with gloves.			
Eye protection	Safety glasses with side-shields conforming to EN166.			
Skin and body	Choose body protection according to the amount and concentration of the			
protection	dangerous substance at the work place.			
Hygiene	Handle in accordance with good industrial hygiene and safety practice.			
measures	Wash hands before breaks and at the end of workday			

### **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

# 9.1 Information on basic physical and chemical properties

**Appearance:** White to off-white powder

Physical state: Solid

pH (as supplied): No data Available

Melting point / freezing point (degrees C): 240

**Boiling point:** No data Available **Flash point:** No data Available

Ignition temperature: No data Available

Upper / lower explosive limits: No data Available

Water solubility: No data Available

### 10: REACTIVITY AND STABILITITY

## 10.1 Chemical stability:

Stable under recommended storage conditions.

## 10.2 Conditions to avoid:

No data available.

### 10.3 Incompatible materials:

Strong oxidizing agents.

# 10.4 Hazardous decomposition:

Hazardous decomposition products formed under fire conditions. - Carbon oxide

Product Name: Equisolon 33.3 mg/g oral powder Issue

Date: 08/2021 Version No: 2021-1



#### **SECTION 11: TOXICOLOGICAL INFORMATION**

### 11.1 Acute toxicity

LD<sub>50</sub> Oral - mouse - 1.680 mg/kg

#### 11.2 Skin corrosion/irritation

No data available

# 11.3 Serious eye damage/irritation

No data available

# 11.4 Respiratory or skin sensitization

No data available

# 11.5 Germ cell mutagenicity

No data available

### 11.6 Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

#### 11.7 Reproductive toxicity

Prednisone can consistently cause cleft palate in rodents and rabbits, but this teratogenic effect is not seen with the human use of prednisone in therapeutic treatments. Retrospective epidemiology studies have associated oral clefting with human pregnancy exposure to corticosteroids based on small numbers of affected children with exposures.

# 11.8 Specific target organ toxicity – single exposure

No data available

# 11.9 Specific target organ toxicity – repeated exposure

No data available

#### 11.10 Aspiration hazard

No data available

#### 11.11 Potential health effects

**Inhalation** May be harmful if inhaled. May cause respiratory tract irritation.

**Ingestion** Harmful if swallowed.

**Skin** May be harmful if absorbed through skin. May cause skin irritation.

**Eyes** May cause eye irritation

## 11.12 Signs and Symptoms of Exposure

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

### 11.13 Additional Information RTECS:

TU4152000

#### **SECTION 12: ECOLOGICAL INFORMATION**

### 12.1 Toxicity

No data available

### 12.2 Persistence and degradability

No data available

### 12.3 Bioaccumulative potential

No data available

### 12.4 Mobility in soil

Product Name: Equisolon 33.3 mg/g oral powder Issue

Date: 08/2021 Version No: 2021-1



No data available

### 12.5 PBT and vPvB assessment

No data available

#### 12.6 Other adverse effects

No data available

#### **SECTION 13: DISPOSAL CONSIDERATIONS**

#### 13.1 Product

Observe all federal, state, and local environmental regulations. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.

### 13.2 Contaminated packaging

Dispose of as unused product.

# **SECTION 14: TRANSPORT INFORMATION**

# 14.1 Land transport (ADR)

Not dangerous goods

#### 14.2 Sea transport (IMDG)

Not dangerous goods

### 14.3 Air transport (IATA)

Not dangerous goods

#### **SECTION 15: REGULATORY INFORMATION**

This safety datasheet complies with the requirements of Regulation (EC) No 1272/2008 (CLP Regulation).

### **SECTION 16: OTHER INFORMATION**

This safety data sheet has been prepared for and applies to this product only. It is based on the information that the supplier was able to provide about the product at the time of preparation. However, Dechra Veterinary Products LLC makes no warranties, express or implied, in relation to the information set out in this Safety Data Sheet, including, without limitation, as to its accuracy or completeness. The information provided is not a quality specification, and is prepared by way of guidance as to the safe handling, use, processing, storage, transportation, disposal and release of the relevant products referred to. The user is responsible for determining whether or not the product is fit for any particular purpose and/or suitable for the user's proposed method of use and application.

Copyright, 2021 Dechra Veterinary Products LLC. All rights reserved.

Product Name: Equisolon 33.3 mg/g oral powder Issue

Date: 08/2021 Version No: 2021-1



Copying and/or downloading of this information for the purpose of properly utilizing Dechra Veterinary Products LLC products is permitted provided that: (1) the information is copied in full with no changes unless prior written agreement is obtained Dechra Veterinary Products LLC, and (2) neither the copy nor the original is resold or otherwise distributed for the purposes of making aprofit thereon.